company background image
NCNA logo

NuCana NasdaqCM:NCNA Stock Report

Last Price

US$1.33

Market Cap

US$2.8m

7D

0%

1Y

-88.7%

Updated

26 Nov, 2024

Data

Company Financials +

NCNA Stock Overview

A clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. More details

NCNA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

NuCana plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NuCana
Historical stock prices
Current Share PriceUS$1.33
52 Week HighUS$19.41
52 Week LowUS$1.23
Beta1.04
11 Month Change-25.70%
3 Month Change-82.05%
1 Year Change-88.68%
33 Year Change-98.05%
5 Year Change-99.28%
Change since IPO-99.67%

Recent News & Updates

Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?

Aug 21
Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?

Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

Mar 14
Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

Recent updates

Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?

Aug 21
Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?

Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

Mar 14
Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

Oct 15
We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

Jul 01
Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Mar 15
Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Nov 30
Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana: An Intriguing 'Sum Of The Parts' Story

Sep 22

NuCana GAAP EPS of -£0.07

Aug 17

NuCana regains Nasdaq compliance

Jul 27

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Jul 13

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

May 02
Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

Jan 17
We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

NuCana: Preparing For A Critical 2022

Dec 08

We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

Sep 30
We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

Sep 11

We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Jun 01
We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

Feb 15
Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

Dec 22
How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

NuCana (NCNA) Investor Presentation - Slideshow

Dec 02

NuCana reports Q3 results

Nov 19

Shareholder Returns

NCNAUS BiotechsUS Market
7D0%4.0%2.0%
1Y-88.7%18.0%32.4%

Return vs Industry: NCNA underperformed the US Biotechs industry which returned 18.3% over the past year.

Return vs Market: NCNA underperformed the US Market which returned 32.6% over the past year.

Price Volatility

Is NCNA's price volatile compared to industry and market?
NCNA volatility
NCNA Average Weekly Movement47.5%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: NCNA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: NCNA's weekly volatility has increased from 36% to 47% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199727Hugh Griffithwww.nucana.com

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.

NuCana plc Fundamentals Summary

How do NuCana's earnings and revenue compare to its market cap?
NCNA fundamental statistics
Market capUS$2.83m
Earnings (TTM)-US$32.65m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NCNA income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£26.00m
Earnings-UK£26.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-11.57
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NCNA perform over the long term?

See historical performance and comparison